Acyl dipeptides as reversible caspase inhibitors. Part 1: Initial lead optimization

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 20, 2002, Pages 2969-2971

  Linton, Steven D ^a   Karanewsky, Donald S ^a   Ternansky, Robert J ^a   Wu, Joe C ^a   Pham, Brian ^a   Kodandapani, Lalitha ^a   Smidt, Robert ^a   Diaz, Jose Luis ^a   Fritz, Lawrence C ^a   Tomaselli, Kevin J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE INHIBITOR; DIPEPTIDE DERIVATIVE; INTERLEUKIN 1BETA CONVERTING ENZYME; LEAD;

ARTICLE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; PEPTIDE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ACYLATION; CASPASES; DIPEPTIDES; ENZYME INHIBITORS; INDICATORS AND REAGENTS; ISOENZYMES; OLIGOPEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 18644370048     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00629-7     Document Type: Article

References (14)

1. (a). For nomenclature of the caspase family, see: Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J.-Y. Cell. 87:1996;171 (b) Thornberry N.A. Chem. Biol. 5:1998;R97 © Black R.A., Kronheim S.R., Sleath P.R. FEBS Lett. 247:1989;386.
2. (a). For nomenclature of the caspase family, see: Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J.-Y. Cell. 87:1996;171 (b) Thornberry N.A. Chem. Biol. 5:1998;R97 © Black R.A., Kronheim S.R., Sleath P.R. FEBS Lett. 247:1989;386.
3. (a). For nomenclature of the caspase family, see: Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J.-Y. Cell. 87:1996;171 (b) Thornberry N.A. Chem. Biol. 5:1998;R97 © Black R.A., Kronheim S.R., Sleath P.R. FEBS Lett. 247:1989;386.
4. (a) Ellis R.E., Yuan J., Horvitz H.R. Annu. Rev. Cell Biol. 7:1991;663.
5. (b) Reed J.C., Tomaselli K.J. Curr. Opin. Biotec. 11:2000;586.
6. (a) Talanian R.V., Brady K.D., Cryns V.L. J. Med. Chem. 43:2000;3351.
7. (b) Lee D., Long S.A., Murray J.H., Adams J.L., Nuttall M.E., Nadeau D.P., Kikly K., Winkler J.D., Sung C.-M., Ryan M.D., Levy M.A., Keller P.M., DeWolf W.E. J. Med. Chem. 44:2001;2015.
8. © Guo Z.-M., Xian M., Zhang W., McGill A., Wang P.G. Bioorg. Med. Chem. 9:2001;99.
9. (d) Shahripour A.B., Plummer M.S., Lunney E.A., Sawyer T.K., Stankovic C.J., Connolly M.K., Rubin J.R., Walker N.P.C., Brady K.D., Allen H.J., Talanian R.V., Wong W.W., Humblet C. Bioorg. Med. Chem. Lett. 11:2001;2779.
10. (e) Shahripour A.B., Plummer M.S., Lunney E.A., Albrecht H.P., Hays S.J., Kostlan C.R., Sawyer T.K., Walker N.P.C., Brady K.D., Allen H.J., Talanian R.V., Wong W.W., Humblet C. Bioorg. Med. Chem. Lett. 10:2002;31
11. (f). For a review of the caspase inhibitor patent literature, see: Ashwell S. Expert Opin. Ther. Pat. 11:2001;1593.
12. These inhibitors were prepared and assayed internally. For preparative route see: Graybill T.L., Dolle R.E., Helaszek C.T., Miller R.E., Ator M.A. Int. J. Peptide Protein Res. 44:1994;173.
13. (a) Karanewsky, D. S.; Kalish, V. J.; Robinson, E. D.; Ullman, B. R. US Patent 6,242,422 B1, 2001.
14. (b) A similar approach has been used by workers at Corvas for the solid phase synthesis of C-terminal argininal-containing peptides. See: Murphy, A. M.; Dagnino, R.; Vallar, P.L.; Trippe, A.J.; Sherman, S.L.; Lumpkin, R.H.; Tamura, S.Y.; Webb, T.R. J. Am. Chem. Soc. 1992, 114, 3156.